Clinical trials: Diabetic Neuropathy Peripheral
Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN)
Oral LAT8881 in Neuropathic Pain
This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.
- Conditions
- Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN), Post Herpetic Neuralgia (PHN)
- Trial name
- NCT03865953
- Testing
- LAT8881
- Where
- 6 sites in Australia, United Kingdom
- Volunteers
- 53 people
- Sponsor
- Lateral Pharma Pty Ltd
Diabetic Neuropathy, Painful
A Study for Treatment of Pain in Patients With Diabetic Neuropathy.
The purpose of this study is to test whether a new treatment will be safe and effective in treating pain. Patients with diabetic peripheral neuropathy will be included.
- Trial name
- NCT00785577
- Testing
- Pregabalin, LY545694 21 mg, LY545694 49 mg
- Where
- 13 sites in United States, Mexico and 1 more
- Volunteers
- 273 people
- Sponsor
- Eli Lilly and Company
Diabetes, Peripheral Neuropathy
Lidocaine for Diabetic Peripheral Neuropathy
Diabetic nerve pain [painful diabetic peripheral neuropathy] is a common medical problem with few reliably effective treatments.
- Conditions
- Diabetes, Peripheral Neuropathy, Pain
- Trial name
- NCT02363803
- Testing
- lidocaine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
Diabetic Neuropathy, Painful
A Study in Painful Diabetic Neuropathy
This study will investigate the efficacy of a combination treatment of duloxetine + pregabalin compared with the maximal dose of each drug in monotherapy, in patients with diabetic peripheral neuropathic pain (DPNP) who have not…
- Trial name
- COMBO-DN (NCT01089556)
- Testing
- Duloxetine, Pregabalin
- Where
- 54 sites in Australia, Canada and 14 more
- Volunteers
- 811 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathy, Painful
Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy and safety of intramuscular administration of Engensis on pain in participants with painful diabetic peripheral neuropathy in the feet and lower legs, as compared to Placebo…
- Trial name
- REGAiN-1A (NCT04469270)
- Testing
- Engensis
- Where
- 16 sites in United States
- Volunteers
- 162 people
- Sponsor
- Helixmith Co., Ltd.
Idiopathic Peripheral Neuropathy
A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
This is an 11-week randomized, double-blind, placebo-controlled trial of Milnacipran 100 mg/d in patients with idiopathic neuropathic pain.
- Trial name
- NCT01288937
- Testing
- Milnacipran
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Diabetic Autonomic Neuropathy
An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes
The focus of this project is cardiovascular diabetic autonomic neuropathy (DAN). DAN affects the nerves that control heart rate and blood flow to the heart in people with diabetes.
- Trial name
- NCT00116207
- Testing
- ORAL ANTIOXIDANT
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Michigan
Diabetic Neuropathy, Painful
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
Patients will be switched from their current medication for painful diabetic peripheral neuropathy to evaluate the safety and efficacy of pregabalin as compared to placebo.
- Trial name
- NCT01057693
- Testing
- pregabalin (Lyrica)
- Where
- 172 sites in United States, Canada and 2 more
- Volunteers
- 633 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Peripheral Neuropathy
Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy
A study to demonstrate the effectiveness of PEMF treatment compared to sham treatment in changing Vibration Perception Threshold (VPT) and Thermal Sensory (QST) in patients with diabetic peripheral neuropathy (DPN) when treatment…
- Trial name
- NCT03077893
- Testing
- Active Provant Therapy System
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Regenesis Biomedical, Inc.
Diabetic Peripheral Neuropathy
Electrical Stimulation for Improving Balance in Diabetes
This is a double-blind randomized clinical trial. Both patients and the podiatrist that will evaluate and monitor study patients will be blinded to electrical stimulation application.
- Trial name
- NCT02337218
- Testing
- SENSUS Pain Management System
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetic Peripheral Neuropathy, Diabetes
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
Evaluation of the efficacy of a low and high dose of LX9211 compared to placebo in reducing pain related to diabetic peripheral neuropathy (DPNP) over an 11 week assessment period.
- Trial name
- RELIEF-DPN 1 (NCT04455633)
- Testing
- LX9211
- Where
- 44 sites in United States
- Volunteers
- 319 people
- Sponsor
- Lexicon Pharmaceuticals
Painful Diabetic Neuropathy
Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain
This post-market study is being conducted to document comparative safety, clinical effectiveness, and cost-effectiveness of the addition of HF10™ therapy to CMM compared with CMM alone in subjects with chronic, intractable…
- Trial name
- SENZA-PDN (NCT03228420)
- Testing
- Senza HF10 Therapy, CMM
- Where
- 4 sites in United States
- Volunteers
- 430 people
- Sponsor
- Nevro Corp
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer